| Literature DB >> 33461595 |
Frances Shiely1,2, Jean Foley3, Amy Stone3, Emma Cobbe3, Shaunagh Browne3, Ellen Murphy3, Maeve Kelsey3, Joanne Walsh-Crowley3, Joseph A Eustace3,4.
Abstract
There is a dearth of literature on best practices for managing clinical trials, and little is understood on the role of the clinical trial manager. The COVID-19 pandemic has brought this into focus, and the continuance of clinical trials worldwide has been catapulted into a state of uncertainty as countries enter lockdown to manage the spread of the virus. Participant retention is an ongoing issue in clinical trials, and the concern is that in the current pandemic environment, attrition will be an issue which could potentially jeopardise trial completion. The current situation has necessitated timely problem solving by the trial manager to ensure trials remain open, and most importantly, that participant safety, paramount in clinical trials, is monitored. The purpose of our study is to highlight key issues arising in the management of clinical trials during a pandemic from first-hand experience in a clinical research facility managing both academic and commercial clinical trials. We offer some practical guidance on solution implementation.Entities:
Keywords: COVID-19; Clinical trials; Pandemic; Participant safety; Trial management
Year: 2021 PMID: 33461595 DOI: 10.1186/s13063-020-05004-8
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279